Environmental, Social, And Governance Report

Overview

The report highlights Amicus's 2023 progress in rare-disease patient access, including regulatory approvals for Pombiliti + Opfolda and treatment access for thousands of patients. It describes sustainability actions with suppliers, employee engagement, and a reported 0% of Scope 1 and 2 GHG emissions because Amicus owns no manufacturing facilities. The report also details ESG oversight by the Board and its committees, including a Board-level Nominating and Corporate Governance Committee. CDP engagement and supplier sustainability reviews are additional highlights.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: Ends 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services